Ferrocenyl Compounds with Masked Phosphates for Anticancer Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for diverse ferrocenyl compounds with both a nucleobase moiety and a hydroxylalkyl group that exhibit anticancer and antiviral activity, as existing ferrocene derivatives have shown limited apoptosis-inducing activity against tumor cells and structural similarities to natural nucleosides can lead to resistance and side effects.
Innovation Solution
Development of ferrocenyl compounds with a heterocyclic moiety linked by various linker groups, including alkylene, alkenylene, and alkynylene chains, and masked phosphate or phosphoramidate groups to enhance phosphorylation and cell membrane transport, allowing for effective incorporation into DNA and termination of synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ferrocene derivatives with nucleobase or hydroxylalkyl groups are used, then antitumor activity is improved, but structural limitations reduce apoptosis-inducing activity
Solution Approach 1:
The patent combines both nucleobase and hydroxylalkyl groups into a single ferrocene derivative molecule, merging the functions of previous separate derivatives. This allows the compound to exhibit both antitumor activity (from nucleobase) and apoptosis-inducing activity (from hydroxylalkyl group), resolving the contradiction by integrating multiple functional moieties into one structure.
Solution Approach 2:
The invention creates a composite molecular structure containing ferrocene core, nucleobase moiety, and hydroxylalkyl group connected by linker chains. This composite approach allows the molecule to possess multiple pharmacological activities simultaneously, overcoming the limitations of single-function ferrocene derivatives.
2Reliability
If nucleoside analogues with structural similarities to natural nucleosides are used, then antiviral or anticancer activity is improved, but resistance and side effects increase
Solution Approach 1:
The patent modifies the molecular parameters of nucleoside analogues by introducing ferrocene core instead of natural sugar rings, changing the structural identity while retaining nucleobase functionality. This parameter change allows the compound to maintain antiviral/anticancer activity through nucleobase recognition while reducing resistance and side effects associated with natural nucleoside similarity.
Solution Approach 2:
The invention preserves the nucleobase moiety for specific biological recognition (local quality for activity) while replacing the sugar portion with ferrocene to reduce harmful similarities to natural nucleosides. This selective retention and modification of structural elements optimizes therapeutic index by maintaining efficacy while reducing resistance and side effects.
3Reliability
If phosphate groups are used to enhance availability to DNA polymerase, then chain termination activity is improved, but cell membrane transport is hindered
Solution Approach 1:
The patent introduces masked phosphate groups as intermediary structures that can cross cell membranes more easily than free phosphate groups. These masked phosphates act as prodrugs that are converted to active triphosphate forms intracellularly, serving as intermediaries between the need for membrane permeability and the need for DNA polymerase recognition.
Solution Approach 2:
The invention performs preliminary phosphorylation masking before cell entry, creating prodrug forms that can be transported across membranes. Once inside the cell, enzymatic processes complete the phosphorylation to active triphosphate forms, allowing the compound to bypass the rate-limiting first phosphorylation step while maintaining cell membrane transport capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ferrocenyl compounds demonstrate significant anticancer and antiviral activity, comparable to commercial drugs like cisplatin and cidofovir, with both the hydroxyl and heterocyclic moieties being crucial for optimal activity, and the use of masked phosphate groups improves efficacy by bypassing the rate-limiting phosphorylation step.
Implementation Method 1
The mechanism of action of nucleoside analogues is believed to proceed via phosphorylation of the primary alcohol by enzymatic processes into a triphosphate
Implementation Method 2
phosphorylation of the primary alcohol by enzymatic processes into a triphosphate
Implementation Method 3
The Protide approach, which uses masked phosphate groups as prodrugs, by-passes this rate determining step and therefore significantly increases the availability of the active compounds to the DNA polymerase
Data Source
AI summary
A ferrocenyl compound having the general formula (I): (I) Het is a substituted or unsubstituted heterocyclic moiety. L1, L2 and L3 are each a linker independently selected from alkylene, alkyleneoxy, alkyleneoxyalkylene, alkylenecarbonyl, alkyleneoxycarbonyl, alkyleneamido, alkyleneoxyamido, alkenylene, alkenyleneoxy, alkenylenecarbonyl, alkenyleneamido, alkynylene, alkynyleneoxy, alkynylenecarbonyl and alkynyleneamido, all of which may be straight chain or branched, substituted or unsubstituted. R1 and R2 are each independently selected from H, substituted or unsubstituted alkyl carbonyl, substituted or unsubstituted aryl carbonyl, substituted or unsubstituted phosphate, substituted or unsubstituted phosphonate and substituted or unsubstituted phosphoramidate. M and n are each 0 or 1 and m+n≠0.1.